Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

Authors Ahrén B

Published Date April 2013 Volume 2013:9 Pages 155—163


Received 4 February 2013, Accepted 13 March 2013, Published 24 April 2013

Bo Ahrén

Department of Clinical Sciences, Lund, Faculty of Medicine, Lund University, Lund, Sweden

Abstract: Type 2 diabetes carries a risk for hypoglycemia, particularly in patients on an intensive glucose control plan as a glucose-lowering strategy, where hypoglycemia may be a limitation for the therapy and also a factor underlying clinical inertia. Glucose-lowering medications that increase circulating insulin in a glucose-independent manner, such as insulin and sulfonylurea therapy, are the most common cause of hypoglycemia. However, other factors such as a delayed or missed meal, physical exercise, or drug or alcohol consumption may also contribute. Specific risk factors for development of hypoglycemia are old age, long duration of diabetes, some concomitant medication, renal dysfunction, hypoglycemia unawareness, and cognitive dysfunction. Hypoglycemia is associated with acute short-term symptoms related to either counterregulation, such as tachycardia and sweating, or to neuroglycopenia, such as irritability, confusion, and in severe cases stupor, coma, and even death. However, there are also long-term consequences of hypoglycemia such as reduced working capacity, weight gain, loss of self-confidence with reduced quality of life, and increased risk for cardiovascular diseases. For both the patients, the health care system, and the society at large, hypoglycemia carries a high cost. Strategies to mitigate the risk of hypoglycemia include awareness of the condition; education of patients, relatives, and health-care providers; and selecting appropriate glucose-lowering medication that also judges the risk for hypoglycemia to prevent this complication. This article summarizes the current knowledge of hypoglycemia and its consequences with a special emphasis on its consequences for the choice of glucose-lowering therapy.

Keywords: type 2 diabetes, hypoglycemia, treatment, sulfonylurea, incretin therapy, insulin

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other articles by this author:

Readers of this article also read:

Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis

Zwikker HE, van Dulmen S, den Broeder AA, van den Bemt BJ, van den Ende CH

Patient Preference and Adherence 2014, 8:1635-1645

Published Date: 25 November 2014

How useful is visual field testing in an African glaucoma clinic?

Lenake M, Cook C, Mustak H, Du Toit N

Clinical Ophthalmology 2014, 8:1767-1771

Published Date: 9 September 2014

Quality of life in elderly patients following coronary artery bypass grafting

Bak E, Marcisz C

Patient Preference and Adherence 2014, 8:289-299

Published Date: 14 March 2014

A case of orbital sebaceous gland carcinoma developing in an anophthalmic socket 65 years after enucleation

Shibata M, Usui Y, Ueda S, Matsumura H, Nagao T, Goto H

Clinical Ophthalmology 2013, 7:1825-1827

Published Date: 16 September 2013

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients

Yamamoto A, Okada AA, Sugitani A, Kunita D, Rii T, Yokota R

Clinical Ophthalmology 2013, 7:757-763

Published Date: 19 April 2013

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

Ansari J, Hussain SA, Ansari A, Glaholm J

Biologics: Targets and Therapy 2013, 7:39-46

Published Date: 28 February 2013

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy

Nemoto R, Miura M, Iwasaki T, Goto H

Clinical Ophthalmology 2012, 6:1633-1638

Published Date: 8 October 2012

Ability of a neuro-ophthalmologist to estimate retinal nerve fiber layer thickness

Pula JH, Kattah JC, Wang H, Marshall J, Eggenberger ER

Clinical Ophthalmology 2012, 6:1477-1481

Published Date: 11 September 2012